Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

View Full Paper
Ask AI
Bookmark
Share

Authors

BDBinod DhakalOAOthman Salim AkhtarAKAdetola A. Kassim

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals clinical features and TP53 mutations indicate poor outcomes in high-risk multiple myeloma patients.

Key Points

  • To understand factors driving early mortality in ultra high-risk multiple myeloma (MM) patients.
  • Conducted a retrospective study of MM patients from two academic centers with early mortality.
  • Analyzed clinical records for demographics, disease characteristics, and treatment history.
  • Performed DNA and RNA sequencing on bone marrow samples for genomic profiling.
  • Identified 16 patients with early mortality within 20 months of diagnosis.
  • Frequent TP53 mutations and other genomic alterations found in patients.
  • Extramedullary disease present in 31% at diagnosis and 56% at relapse.

Cite This Study

Dhakal et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0behttps://doi.org/10.1182/blood-2025-2240
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  2. 2High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma.2025
  3. 3MULTIPLE MYELOMA IN THE ERA OF PRECISION MEDICINE: RECENT ADVANCES IN PATHOGENESIS, DIAGNOSIS, AND TREATMENT2025
  4. 4BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025
  5. 5Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment2025